From the outside, clinical supply chain can look like logistics. You make the material, you ship it where it needs to go, you keep it cold along the way. How hard can it be? I understand why people think that, because the broad strokes really are that simple. The complexity is not in the broad strokes. It is in the hundred small decisions underneath them, and that is exactly where experience earns its keep.
The trouble is that experience in this area is easy to undervalue, because the problems it prevents are mostly invisible. When an experienced person resolves something in a sentence, it looks like they just happened to know the answer. What actually happened is they recognized a familiar situation and kept the team from spending weeks on it. Nothing went wrong, so it is hard to see what was saved. That is the nature of the expertise. It shows up as an absence of problems, which is the easiest kind of value to overlook.
Where you do see it is in the small moments, when a team without much clinical supply experience runs into something that looks like a real problem and is not. They overanalyze it. They engineer around it. They spin for weeks on a question an experienced person would have closed quickly, and the cost is real, in time, in money, in people's energy.
A small example. I was once on a program where the product shipped to the patient's home and sat there a few days before a clinician came to administer it. That short storage window generated a surprising amount of debate. How do we guarantee the temperature in the patient's refrigerator? Should we ship a monitor with the drug for the clinician to check? The "keep out of reach and sight of children" line prompted talk of opaque bags and extra boxes to disguise the product in the home.
The instinct behind all of it was good. People wanted to be careful, and care with investigational product is a reflex you want. But it missed something that experience makes obvious: the label is an instruction to the patient, not a mandate the manufacturer has to enforce inside someone's home. "Keep out of reach and sight of children" tells the person holding the drug what to do. The storage conditions tell them how to keep it. We had stability data that supported the window, and the patient is responsible for following the instructions on their medication, the same as they are for anything in their medicine cabinet. Letting that responsibility sit where it belongs is also the most realistic version of the commercial world, where nobody ships a monitor home with every prescription. It was not a hard call. It just required knowing which problems are actually yours to solve.
None of this is a knock on anyone. The misread is common precisely because it is well-meaning, and because nothing about clinical supply announces its own complexity from the outside. But that is the case for experience, not against it. The value of someone who has done this before is not that they work harder or care more. It is that they know which of the hundred small things deserve a week and which deserve a sentence, and they can tell the difference before the week is gone.
Which is really an argument for getting that experience in the room earlier than most companies do. There is a tendency to see supply chain as something you staff up later, once a program is further along and the volumes are real. By then you have already spent money and time on the small things, and you have made early decisions that are harder to walk back than they would have been to get right the first time. An experienced supply chain person in the room during early clinical studies is not a luxury for that stage. It is often what keeps the stage from costing more than it should.
And it does not have to be a full-time hire. A lot of early-stage companies do not need a dedicated supply chain leader yet, and that is a reasonable thing to weigh against a lean budget. But the choice is not between a full headcount and nobody. Fractional and embedded support exists precisely for this, enough experience in the room to steer the hundred small decisions well, without carrying a role the program is not ready for. The mistake is not failing to hire a full team early. It is assuming that because you do not need the full team yet, you do not need the experience yet either. Those are not the same thing.